BIORESTORATIVE THERAPIES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K | $77.0K | $130.0K | $111.0K |
| Cost of Revenue | $23.8K | $28.1K | — | — | — | — | — | — |
| Gross Profit | $335.9K | $372.9K | $145.8K | — | — | — | — | — |
| Gross Margin | 93.4% | 93.0% | 100.0% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $10.1M | $6.7M | $4.0M | $3.5M | $729.1K | $876.8K | $1.7M | $1.5M |
| SG&A Expense | $5.9M | $5.2M | $11.3M | $15.6M | $25.6M | $1.8M | $4.6M | $4.0M |
| Operating Income | $-15.6M | $-11.6M | $-15.2M | $-19.0M | $-26.3M | $-2.8M | $-8.4M | $-7.6M |
| Operating Margin | -4,350.1% | -2,881.6% | -10,439.5% | -15,838.1% | -57,191.0% | -3,574.1% | -6,486.2% | -6,889.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-14.2M | $-9.0M | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-14.2M | $-9.0M | $-10.4M | $-13.2M | $-44.3M | $-11.3M | $-14.6M | $-12.5M |
| Net Margin | -3,959.4% | -2,239.2% | -7,145.2% | -11,037.0% | -96,311.5% | -14,639.9% | -11,267.6% | -11,277.3% |
| EPS (Basic) | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-12.43 | $-9.52 | $-0.22 | $-0.55 |
| EPS (Diluted) | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-12.43 | $-9.52 | $-0.22 | $-0.55 |
| Shares Outstanding (Basic) | 9.0M | 7.8M | 4.2M | 3.6M | 3.6M | 8.59B | 233.6M | 35.2M |
| Shares Outstanding (Diluted) | 9.0M | 7.8M | 4.2M | 3.6M | 3.6M | 8.59B | 233.6M | 35.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |